CompletedPhase 2NCT01290120
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Northern Italy Leukemia Group
- Principal Investigator
- Renato Bassan, MDUSC Ematologia Ospedali Riuniti di Bergamo
- Intervention
- Chemotherapy-Rituximab combination(drug)
- Enrollment
- 182 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2002 – 2014
Study locations (12)
- Divisione di Ematologia e TMO, Ospedale San Maurizio, Bolzano, (bz), Italy
- Ematologia e centro TMO - Ospedale Armando Businco, Cagliari, (ca), Italy
- S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle, Cuneo, (cn), Italy
- Onco-Ematologia - Ospedale Civile, Noale, (ve), Italy
- Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy
- USC Ematologia Ospedali Riuniti di Bergamo, Bergamo, BG, Italy
- Divisione Ematologia Spedali Civili, Brescia, BS, Italy
- Ematologia - AOU Careggi, Florence, FI, Italy
- Ematologia e TMO - Ospedale San Raffaele, Milan, MI, Italy
- Ematologia - TMO - Ospedale San Gerardo, Monza, MI, Italy
- Ematologia Ospedale San Bortolo, Vicenza, VI, Italy
- USC Ematologia Ospedali Riuniti di Bergamo, Bergamo, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01290120 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital